Welcome to our dedicated page for Arcutis Biotherapeutics SEC filings (Ticker: ARQT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arcutis Biotherapeutics filings document regulatory disclosures for a Nasdaq-listed commercial-stage biopharmaceutical company developing and commercializing dermatology treatments. Its Form 8-K reports furnish quarterly and annual financial-results releases, business updates, ZORYVE product-revenue commentary, clinical and regulatory program updates, and securities information for its common stock listed on the Nasdaq Global Select Market.
Arcutis proxy and governance filings cover annual meeting matters, executive compensation, equity awards, board composition, and shareholder voting items. Other material-event disclosures address director changes, compensatory arrangements, consulting or transition agreements, and related governance matters within the company’s public-company reporting framework.
Arcus Biotherapeutics reports that Jennison Associates LLC beneficially owns 4,980,770 shares of Common Stock, representing 4.0% of the class as reported. The filing lists sole voting power of 4,980,770 shares and shared dispositive power of 4,980,770. The filing is dated 03/31/2026 and signed on 05/06/2026.
Arcutis Biotherapeutics reported strong top-line growth but remained unprofitable for the quarter ended March 31, 2026. Total product revenue reached $105.4 million, up from $63.8 million a year earlier, driven by broader adoption of ZORYVE cream and foam across psoriasis, seborrheic dermatitis, and atopic dermatitis indications in the U.S. and Canada.
The company recorded a net loss of $11.3 million, a significant improvement from a $25.1 million loss in the prior-year quarter, with net loss per share narrowing to $0.09 from $0.20. Operating cash flow turned positive at $2.2 million versus a $30.4 million outflow a year earlier.
Arcutis ended the quarter with $224.3 million in cash, cash equivalents, restricted cash, and marketable securities and had $100.0 million in debt outstanding. Management believes current capital resources will fund operations for at least 12 months. The company is investing in growth, including a $10.0 million milestone tied to starting a Phase 1a/1b trial for ARQ-234 in moderate-to-severe atopic dermatitis.
Arcutis Biotherapeutics reported strong first quarter 2026 growth driven by its dermatology franchise ZORYVE. Net product revenue was $105.4 million, up 65% from Q1 2025 but down 17% from Q4 2025 due to typical first-quarter deductible resets and insurance changes.
By product, Q1 2026 revenue was $32.7 million from ZORYVE cream 0.3%, $49.6 million from ZORYVE foam 0.3%, $21.7 million from ZORYVE cream 0.15%, and $1.4 million from ZORYVE cream 0.05%. Net loss narrowed to $11.3 million or $0.09 per share, compared with a $25.1 million loss a year earlier.
The company generated $2.2 million of positive operating cash flow and ended March 31, 2026 with $224.3 million in cash, cash equivalents, restricted cash, and marketable securities. Arcutis reaffirmed its expectation for 2026 net product revenue between $480 million and $495 million and highlighted pipeline progress, including an sNDA for ZORYVE cream 0.05% in infants, a June 29, 2026 PDUFA date for ZORYVE cream 0.3%, enrollment completion for a pediatric MUSE trial, and initiation of a Phase 1a/1b study of investigational biologic ARQ-234.
Arcutis Biotherapeutics director Howard G. Welgus sold shares of company stock in a planned transaction. On May 1, 2026, he completed an open-market sale of 7,144 shares of Arcutis common stock at a weighted average price of $22.9871 per share.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 11, 2025, which is scheduled to run through May 29, 2026. Following this transaction, Welgus directly holds 32,600 Arcutis common shares.
Arcutis Biotherapeutics filing reports an intended sale of 684 shares of Common Stock related to restricted stock vesting on 05/01/2026. The filing also lists prior sales by Patrick Burnett of 9,794 shares on 02/04/2026 for $252,748.08 and 6,287 shares on 03/02/2026 for $158,319.86.
Arcutis Biotherapeutics filed a Form 144 notice reporting proposed disposition of 1,341 shares of Common Stock tied to Restricted Stock Vesting with an effective date of 05/01/2026. The filing also lists a prior sale of 2,853 shares on 03/02/2026. The document names a broker (Merrill Lynch) and shows 124,033,382 shares outstanding as of 05/04/2026.
Arcutis Biotherapeutics submitted a Form 144 notice for the proposed sale of 3,172 shares of Common Stock, tied to restricted stock vesting on 05/01/2026. The filing notes a prior sale of 37,349 shares on 03/02/2026 valued at $940,526.25.
Arcutis Biotherapeutics submitted a Form 144 notice reporting proposed sales of Common stock linked to restricted stock vesting. The filing lists vesting events of 5,152 shares (05/01/2025), 2,220 shares (11/14/2025), and 884 shares (05/01/2026). It also records sales of 3,325 shares on 02/27/2026 and 8,733 shares on 03/02/2026 with reported dollar amounts.
Arcutis Biotherapeutics Inc. notice: proposed sales of Common Stock by Howard Welgus reported on a Form 144. The excerpt lists three dispositions of 10,000 shares each on 02/02/2026, 03/02/2026, and 04/01/2026 with proceeds shown as $250,482.69, $256,517.50, and $238,800 respectively.
Security details include Common Stock trading on NASDAQ and a reported shares outstanding figure of 124,033,382 shares as of 05/01/2026.